Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Triple negative
•
Breast Cancer, Non-metastatic
What neoadjuvant chemotherapy regimen would you choose for a triple positive (ER+/PR+/HER2+) cT2N1 G3 breast cancer for an elderly patient (80 y/o)?
Related Questions
Would you offer adjuvant chemotherapy for triple negative invasive papillary carcinoma of breast?
Would you recommend adjuvant endocrine therapy in combination with immunotherapy for triple negative metaplastic breast cancer with residual disease that is ER strongly positive?
Would you offer neoadjuvant chemoimmunotherapy per KEYNOTE 522 for a patient with clinical stage IIB triple-negative breast cancer with apocrine histology or recommend surgery first?
How would you treat a young premenopausal female with triple negative inflammatory breast cancer who progressed on carboplatin/paclitaxel/pembrolizumab (KEYNOTE 522), but didn't receive anthracycline portion and has a positive BRCA2 mutation?
Would you offer adjuvant AC + pembrolizumab for a triple negative breast cancer patient whose tumor progressed on carboplatin + paclitaxel + pembrolizumab on KEYNOTE-522 and required urgent surgery (ypT3 ypN0)? If not, would you lean towards adjuvant capecitabine?
What are your top takeaways in Medical Oncology from SABCS 2024?
Does the degree of hormone receptor positivity influence your decision to perform Oncotype testing?
Would you offer adjuvant endocrine therapy for a postmenopausal female with stage III triple positive multicentric breast cancer (DCIS and invasive ductal carcinoma) s/p neoadjuvant TCHP followed by bilateral mastectomy with no residual disease?
How do you manage a patient with early stage HER2+ breast cancer patient who progressed on mastectomy after completing neoadjuvant TCHP?
Would you consider addition of adjuvant Capecitabine to TDM-1 in a patient with residual disease after neoadjuvant therapy (TCHP) for biopsy proven HR- HER2 positive breast cancer if residual disease after mastectomy shows HR- HER2 negative disease?
